Cite as: 21 CNCA § 2204

The controlled substances listed in this section are included in Schedule I.

1. Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

a. Acetylmethadol,

b. Allylprodine,

c. Alphacetylmethadol,

d. Alphameprodine,

e. Alphamethadol,

f. Benzethidine,

g. Betacetylmethadol,

h. Betameprodine,

i. Betamethadol,

j. Betaprodine,

k. Clonitazene,

l. Dextromoramide,

m. Dextrorphan (except its methyl ether),

n. Diampromide,

o. Diethylthiambutene,

p. Dimenoxadol,

q. Dimepheptanol,

r. Dimethylthiambutene,

s. Dioxaphetyl butyrate,

t. Dipipanone,

u. Ethylmethylthiambutene,

v. Etonitazene,

w. Etoxeridine,

x. Furethidine,

y. Hydroxypethidine,

z. Ketobemidone,

aa. Levomoramide,

bb. Levophenacylmorphan,

cc. Morpheridine,

dd. Noracymethadol,

ee. Norlevorphanol,

ff. Normethadone,

gg. Norpipanone,

hh. Phenadoxone,

ii. Phenampromide,

jj. Phenomorphan,

kk. Phenoperidine,

ll. Piritramide,

mm. Proheptazine,

nn. Properidine,

oo. Racemoramide,

pp. Trimeperidine.

2. Any of the following opium derivatives, their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

a. Acetorphine,

b. Acetyldihydrocodeine,

c. Benzylmorphine,

d. Codeine methylbromide,

e. Codeine–N–Oxide,

f. Cyprenorphine,

g. Desomorphine,

h. Dihydromorphine,

i. Etorphine,

j. Heroin,

k. Hydromorphinol,

l. Methyldesorphine,

m. Methylhydromorphine,

n. Morphine methylbromide,

o. Morphine methylsulfonate,

p. Morphine–N–oxide,

q. Myrophine,

r. Nicocodeine,

s. Nicomorphine,

t. Normorphine,

u. Phoclodine,

v. Thebacon.

3. Any material, compound, mixture or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

a. 3, 4–methylenedioxy amphetamine,

b. 5–methoxy–3, 4–methylenedioxy amphetamine,

c. 3, 4, 5–trimethoxy amphetamine,

d. Bufotenine,

e. Diethyltryptamine,

f. Dimethyltryptamine,

g. 4–methyl–2, 5–dimethoxyamphetamine,

h. Ibogaine,

i. Lysergic acid diethylamide,

j. Mescaline,

k. N-ethyl–3–piperidyl benzilate,

l. N-methyl–3–piperidyl benzilate,

m. Psilocybin,

n. Psilocyn,

o. 2, 5 dimenthoxyamphetamine,

p. 4 bromo–2, 5–dimethoxyamphetamine,

q. 4 methoxyamphetamine,

r. Cyclohexamine,

s. Thiphene analog of phencyclidine, also known as 1–(1–(2–thienyl) cyclohexl) piperidine; 2–thienyl analog of phencyclidine; TPCP, TCP,

t. Phencyclidine (PCP),

u. Pyrrolidine analog for phencyclidine, also known as1–(1–phenycly-clohexyl)—pyrrolidine, PCPy, PHP.

4. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having stimulant or depressant effect on the central nervous system:

a. Fenethylline,

b. Mecloqualone,

c. N-ethylamphetamine,

d. Methaqualone.

Historical Data

LA 3–91, eff. February 9, 1991. Amended LA 28-20, eff. December 14, 2020.

Renumbered from 63 CNCA § 2–204.